AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Smart financial goals help you define clear targets for your money. This intro explains the concept and sets you up with practical steps to start planning today.
18,452 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Insider moves can signal a lot about a company’s near-term plans and risk. This deep dive looks at Adaptive Biotechno...
A July 12 KBW report argues artificial intelligence will fortify the industry’s largest lenders rather than upend the...
A proposed bill would end the Social Security earnings test for those under full retirement age, potentially increasi...
A trading halt and a sharp drop put Lucid in the spotlight, but the company pushed back on bankruptcy chatter. This g...
Morgan Stanley's 2026 outlook hinges on wealth management growth, trading environment, and disciplined capital manage...
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A high-profile insider move by Pinterest’s leadership drew attention from investors. This deep dive explains what the...
Markets react to political echoes of Jimmy Carter as Trump faces Iran tensions and inflation. This piece explores wha...
In 2022, the market dropped hard, but some dividend-focused funds held up better than the broad index. This article e...
Richtech Robotics faced a sharp pullback in early 2026, driven by execution missteps and market concerns. This piece ...
A loose, little-regulated lending network is stepping in to help small businesses cover tariffs quickly, but with ste...